Skip to main content
Erschienen in: Clinical and Experimental Nephrology 5/2018

29.03.2018 | Original article

Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study

verfasst von: Teppei Okamoto, Shingo Hatakeyama, Yoshimi Tanaka, Kengo Imanishi, Tooru Takashima, Fumitada Saitoh, Takuya Koie, Tadashi Suzuki, Chikara Ohyama

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Erythropoiesis-stimulating agent (ESA) responsiveness is related to the nutritional status of patients on hemodialysis (HD). Serum butyrylcholinesterase (BChE), an alpha-glycoprotein, may decrease in case of malnutrition. We investigated whether BChE was independently related to ESA resistance in patients on HD.

Methods

The laboratory data and ESA resistance index (ERI), defined as ESA dosage per week divided by dry weight and hemoglobin, were investigated in 215 patients on HD between July and September 2017. Malnutrition was defined as Geriatric Nutritional Risk Index (GNRI) of < 91.2. The patients were stratified into two groups: ERI-high (ERI ≥ 9.44) and ERI-low (ERI < 9.44) groups. Variables such as patient’s background, medication, and laboratory data were compared between the two groups. The optimal cutoff value of BChE for higher ERI was determined using receiver operating characteristic analysis. Factors independently associated with higher ERI were determined using multivariate logistic regression analysis.

Results

The median and optimal cutoff values of ERI and BChE were 6.51 and 200 IU/L, respectively. The study included 71 (33%) and 144 (67%) patients in the ERI-high and ERI-low groups, respectively. Significant between-group differences were observed concerning age, hemoglobin, ESA dose, lipid profiles, serum albumin, body mass index, GNRI, iron metabolism markers, ferric medicines, and BChE. Multivariate analysis showed that BChE < 200 IU/L (odds ratio 3.67; 95% confidence interval 1.73–7.77) continued to be an independent factor associated with higher ERI after adjusting for potential confounders, which was a similar odds ratio as GNRI < 91.2.

Conclusion

BChE may be an independent indicator of ESA resistance.
Literatur
1.
Zurück zum Zitat Akizawa T, Pisoni RL, Akiba T, Saito A, Fukuhara S, Asano Y, et al. Japanese haemodialysis anaemia management practices and outcomes (1999‒2006); results from the DOPPS. Nephrol Dial Transpl. 2008;23:3643‒3653.CrossRef Akizawa T, Pisoni RL, Akiba T, Saito A, Fukuhara S, Asano Y, et al. Japanese haemodialysis anaemia management practices and outcomes (1999‒2006); results from the DOPPS. Nephrol Dial Transpl. 2008;23:3643‒3653.CrossRef
2.
Zurück zum Zitat Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, et al. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005;149:408–13.CrossRefPubMed Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, et al. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005;149:408–13.CrossRefPubMed
3.
Zurück zum Zitat Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transpl. 2013;28:1936–45.CrossRef Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transpl. 2013;28:1936–45.CrossRef
4.
Zurück zum Zitat Davis L, Britten JJ, Morgan M. Cholinesterase Its significance in anaesthetic practice. Anaesthesia. 1997;52:244–60.CrossRefPubMed Davis L, Britten JJ, Morgan M. Cholinesterase Its significance in anaesthetic practice. Anaesthesia. 1997;52:244–60.CrossRefPubMed
5.
Zurück zum Zitat Ogunkeye OO, Roluga AI. Serum cholinesterase activity helps to distinguish between liver disease and non-liver disease aberration in liver function tests. Pathophysiology. 2006;13:91–3.CrossRefPubMed Ogunkeye OO, Roluga AI. Serum cholinesterase activity helps to distinguish between liver disease and non-liver disease aberration in liver function tests. Pathophysiology. 2006;13:91–3.CrossRefPubMed
6.
Zurück zum Zitat Lampón N, Hermida-Cadahia EF, Riveiro A, Tutor JC. Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol. 2012;11:356–63.PubMed Lampón N, Hermida-Cadahia EF, Riveiro A, Tutor JC. Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol. 2012;11:356–63.PubMed
7.
Zurück zum Zitat Hubbard RE, O’Mahony MS, Calver BL, Woodhouse KW. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008;64:895–900.CrossRefPubMed Hubbard RE, O’Mahony MS, Calver BL, Woodhouse KW. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008;64:895–900.CrossRefPubMed
8.
Zurück zum Zitat Gu SZ, Zhao XH, Quan P, Li SB, Pan BR. Alterations of serum cholinesterase in patients with gastric cancer. World J Gastrenterol. 2005;11:4604–6.CrossRef Gu SZ, Zhao XH, Quan P, Li SB, Pan BR. Alterations of serum cholinesterase in patients with gastric cancer. World J Gastrenterol. 2005;11:4604–6.CrossRef
9.
Zurück zum Zitat Cucuianu M, Nistor T, Hâncu N, Orbai P, Muscurel C, Stoian I. Serum cholinesterase activity correlates with serum insulin, C-peptide and free fatty acids levels in patients with type 2 diabetes. Rom J Intern Med. 2002;40:43–51.PubMed Cucuianu M, Nistor T, Hâncu N, Orbai P, Muscurel C, Stoian I. Serum cholinesterase activity correlates with serum insulin, C-peptide and free fatty acids levels in patients with type 2 diabetes. Rom J Intern Med. 2002;40:43–51.PubMed
10.
Zurück zum Zitat Paes AM, Carniatto SR, Francisco FA, Brito NA, Mathias PC. Acetylcholinesterase activity changes on visceral organs of VMH lesion-induced obese rats. Int J Neurosci. 2006;116:1295–302.CrossRefPubMed Paes AM, Carniatto SR, Francisco FA, Brito NA, Mathias PC. Acetylcholinesterase activity changes on visceral organs of VMH lesion-induced obese rats. Int J Neurosci. 2006;116:1295–302.CrossRefPubMed
11.
Zurück zum Zitat Nomura F, Ohnishi K, Koen H, Hiyama Y, Nakayama T, Itoh Y,et al. Serum cholinesterase in patients with fatty liver. J Clin Gastroenterol. 1986;8:599–602.CrossRefPubMed Nomura F, Ohnishi K, Koen H, Hiyama Y, Nakayama T, Itoh Y,et al. Serum cholinesterase in patients with fatty liver. J Clin Gastroenterol. 1986;8:599–602.CrossRefPubMed
12.
Zurück zum Zitat Calderon-Margalit R, Adler B, Abramson JH, Gofin J, Kark JD. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem. 2006;52:845–52.CrossRefPubMed Calderon-Margalit R, Adler B, Abramson JH, Gofin J, Kark JD. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem. 2006;52:845–52.CrossRefPubMed
13.
14.
Zurück zum Zitat Koie T, Ohyama C, Mikami J, Iwamura H, Fujita N, Sato T, et al. Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy. Sci World J. 2014;2014:948305.CrossRef Koie T, Ohyama C, Mikami J, Iwamura H, Fujita N, Sato T, et al. Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy. Sci World J. 2014;2014:948305.CrossRef
15.
Zurück zum Zitat Garcia SC, Wyse AT, Valentini J, Roehrs M, Moro AM, Paniz C, et al. Butyrylcholinesterase activity is reduced in haemodialysis patients: is there association with hyperhomocysteinemia and/or oxidative stress? Clin Biochem. 2008;41:474–9.CrossRefPubMed Garcia SC, Wyse AT, Valentini J, Roehrs M, Moro AM, Paniz C, et al. Butyrylcholinesterase activity is reduced in haemodialysis patients: is there association with hyperhomocysteinemia and/or oxidative stress? Clin Biochem. 2008;41:474–9.CrossRefPubMed
16.
Zurück zum Zitat Cremieux PY, Van Audenrode M, Lefebvre P. The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. Curr Med Res Opin. 2006;22:2329‒2336.CrossRef Cremieux PY, Van Audenrode M, Lefebvre P. The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. Curr Med Res Opin. 2006;22:2329‒2336.CrossRef
17.
Zurück zum Zitat Eriguchi R, Taniguchi M, Ninomiya T, Hirakata H, Fujimi S, Tsuruya K, et al. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study. J Nephrol. 2015;28:217–25.CrossRefPubMed Eriguchi R, Taniguchi M, Ninomiya T, Hirakata H, Fujimi S, Tsuruya K, et al. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study. J Nephrol. 2015;28:217–25.CrossRefPubMed
18.
Zurück zum Zitat Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82:777–83.CrossRefPubMed Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82:777–83.CrossRefPubMed
19.
Zurück zum Zitat Yamada K, Furuya R, Takita T, Maruyama Y, Yamaguchi Y, Ohkawa S, et al. Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr. 2008;87:106–13.CrossRefPubMed Yamada K, Furuya R, Takita T, Maruyama Y, Yamaguchi Y, Ohkawa S, et al. Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr. 2008;87:106–13.CrossRefPubMed
21.
Zurück zum Zitat McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK. Mendelssohn. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int. 2010;78:215–23.CrossRefPubMed McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK. Mendelssohn. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int. 2010;78:215–23.CrossRefPubMed
22.
Zurück zum Zitat Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1077–83.CrossRefPubMedPubMedCentral Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1077–83.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S,et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transpl. 2006;21:991–8.CrossRef Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S,et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transpl. 2006;21:991–8.CrossRef
24.
Zurück zum Zitat Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol. 2004;15(Suppl 1):S21–4.CrossRefPubMed Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol. 2004;15(Suppl 1):S21–4.CrossRefPubMed
25.
Zurück zum Zitat Mallick S, Rafiroiu A, Kanthety R, Iqbal S, Malik R, Rahman M. Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Blood Purif. 2012;33:238–44.CrossRefPubMed Mallick S, Rafiroiu A, Kanthety R, Iqbal S, Malik R, Rahman M. Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Blood Purif. 2012;33:238–44.CrossRefPubMed
26.
27.
Zurück zum Zitat Panichi V, Cupisti A, Rosati A, Di Giorgio A, Scatena A, Menconi O, et al. Geriatric nutritional risk index is a strong predictor of mortality in hemodialysis patients: data from the Riscavid cohort. J Nephrol. 2014;27:193–201.CrossRefPubMed Panichi V, Cupisti A, Rosati A, Di Giorgio A, Scatena A, Menconi O, et al. Geriatric nutritional risk index is a strong predictor of mortality in hemodialysis patients: data from the Riscavid cohort. J Nephrol. 2014;27:193–201.CrossRefPubMed
28.
Zurück zum Zitat Santarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle. 2013;4:31–9.CrossRefPubMed Santarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle. 2013;4:31–9.CrossRefPubMed
29.
Zurück zum Zitat Sukkar SG, Gallo F, Borrini C, Vaccaro A, Marchello C, Boicelli R, et al. Effects of a new mixture of essential amino acids (Aminotrofic(®)) in malnourished haemodialysis patients. Med J Nutr Metab. 2012;5:259–66.CrossRef Sukkar SG, Gallo F, Borrini C, Vaccaro A, Marchello C, Boicelli R, et al. Effects of a new mixture of essential amino acids (Aminotrofic(®)) in malnourished haemodialysis patients. Med J Nutr Metab. 2012;5:259–66.CrossRef
30.
Zurück zum Zitat Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transpl. 2001;16:1863–9.CrossRef Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transpl. 2001;16:1863–9.CrossRef
31.
Zurück zum Zitat Ostergaard D, Viby-Mogensen J, Hanel HK, Skovgaard LT. Half-life of plasma cholinesterase. Acta Anaesthesiol Scand. 1988;32:266–9.CrossRefPubMed Ostergaard D, Viby-Mogensen J, Hanel HK, Skovgaard LT. Half-life of plasma cholinesterase. Acta Anaesthesiol Scand. 1988;32:266–9.CrossRefPubMed
32.
Zurück zum Zitat Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 1998;31:93–100.CrossRefPubMed Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 1998;31:93–100.CrossRefPubMed
33.
Zurück zum Zitat Stojanov MD, Jovicić DM, Djurić SP, Konjević MM, Todorović ZM, Prostran MS. Butyrylcholinesterase activity and mortality risk in hemodialysis patients: comparison to hsCRP and albumin. Clin Biochem. 2009;42:22–6.CrossRefPubMed Stojanov MD, Jovicić DM, Djurić SP, Konjević MM, Todorović ZM, Prostran MS. Butyrylcholinesterase activity and mortality risk in hemodialysis patients: comparison to hsCRP and albumin. Clin Biochem. 2009;42:22–6.CrossRefPubMed
34.
Zurück zum Zitat Azuma S, Higashiue S, Kawahira T, Matsubayashi K, Tonda H, Komooka M, et al. Long-term results following aortic valve replacement for aortic valve stenosis in patients with dialysis-dependent renal failure and risk factors for prognosis. Jpn J Vasc Surg. 2013;4:274–8 (Japanese). Azuma S, Higashiue S, Kawahira T, Matsubayashi K, Tonda H, Komooka M, et al. Long-term results following aortic valve replacement for aortic valve stenosis in patients with dialysis-dependent renal failure and risk factors for prognosis. Jpn J Vasc Surg. 2013;4:274–8 (Japanese).
Metadaten
Titel
Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study
verfasst von
Teppei Okamoto
Shingo Hatakeyama
Yoshimi Tanaka
Kengo Imanishi
Tooru Takashima
Fumitada Saitoh
Takuya Koie
Tadashi Suzuki
Chikara Ohyama
Publikationsdatum
29.03.2018
Verlag
Springer Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 5/2018
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-018-1569-z

Weitere Artikel der Ausgabe 5/2018

Clinical and Experimental Nephrology 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.